Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jan 2000
Randomized Controlled Trial Clinical TrialPretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
The purpose of this randomized, two-period crossover study was to determine the pharmacokinetics of orally administered topotecan in the presence and absence of oral ranitidine. ⋯ Administration of ranitidine prior to oral topotecan resulted in a similar extent of absorption. A slightly faster rate of absorption of topotecan was also observed, which is unlikely to be of clinical significance. Dosage adjustments of orally administered topotecan should not be necessary in patients who are pretreated with ranitidine, an H2 antagonist, or another agent that comparably raises gastric pH.